NICE have approved Tecentriq® (atezolizumab), for NHS patients with advanced bladder cancer who have relapsed following prior treatment.
Researchers have reported that children with incurable brain tumors could benefit from a potentially life-extending treatment, if genetic testing is utilized to personalize their therapy. This personalized treatment has previously only been used in adults.
A novel three-dimensional high-throughput screening approach allows researchers to identify inducers of a mutant KRAS selective lethal phenotype.
In this review article find out which treatment plan is most appropriate for different groups of acute lymphoblastic leukemia patients.
This article describes a mathematical modeling framework to facilitate the prediction of clinical efficacy and toxicity of investigational antineoplastic agents.
Find out the key features of the breast tumor microenvironment as well as putative predictive biomarkers established in other tumor types. Insights from both fields could guide future studies to enable personalized breast cancer immunotherapy.